Mayne Pharma Group Ltd. · ASX:MYX

Mayne Pharma — UBS Emerging Companies Conference 2013

13 slides from Mayne Pharma's conference presentation, Apr 10, 2013

  1. Slide 1: Mayne Pharma Group Limited Company Presentation

    For personal use only Mayne Pharma Group Limited Company Presentation UBS Emerging Companies Conference 10 April 2013 Scott A Richards, CEO

  2. Slide 2: A specialty pharmaceutical company with an increasingly diversified portfolio

    A specialty pharmaceutical company with an increasingly diversified portfolio of products, technologies and footprint For personal use only Direct access to 5 products filed the world’s Proforma FY12 with the FDA largest revenue and a further 12 pharmaceutical >$100m under market development SUBACAP

  3. Slide 3: Overview of Mayne Pharma

    Overview of Mayne Pharma Executive summary FY12 pro forma1 sales revenue by product For personal use only  Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products distributed directly or through distribution partners and also provid

  4. Slide 4: Evolution of Mayne Pharma

    Evolution of Mayne Pharma For personal use only 1845 1970s  Development of enteric coated erythromycin (Eryc®)  FDA approval and first US sales of Eryc® by Warner Lambert (Chilcott) FH Faulding & Co 1980s  Salisbury site acquired in 1983  Development of delayed-release doxycycline capsules (Dory

  5. Slide 5: Mayne Pharma's international footprint

    Mayne Pharma’s international footprint For personal use only Midlothian  1,000m2 commercial and distribution facility in Montgomery, Alabama Metrics’ facility  14.6 hectare facility at Greenville, North Carolina has 9,200m2 of manufacturing space. FDA inspected and cGMP compliant. Annual productio

  6. Slide 6: Mayne Pharma's expanding capabilities

    Mayne Pharma’s expanding capabilities 2011 2013 For personal use only • Tablets and capsules • Tablets and capsules Products • Liquids and creams • Liquids and creams • 4 branded products sold in Australia (Astrix®, • 6 branded products sold in Australia (Astrix®, Doryx®, Eryc®, Magnoplasm®) Doryx®,

  7. Slide 7: 1H13 financial results summary

    1H13 financial results summary For personal use only ● Transformational period for Mayne Pharma following the Metrics and Kapanol® acquisitions ● Metrics acquisition tracking to top end of guidance: Guidance Actual Revenue $25–30m $27m In guidance - Mayne Pharma $19–22m $19m In guidance - Metrics $6

  8. Slide 8: Mayne Pharma business segments

    Mayne Pharma business segments For personal use only Mayne Pharma Mayne Pharma Metrics Metrics Australia Global Products Contract Services (manufactures, markets & (manufactures & out-licenses (manufactures, markets & (provides contract distributes branded & branded pharmaceuticals to distributes ge

  9. Slide 9: Research and development – generic pipeline

    Research and development – generic pipeline For personal use only ● 17 generic products under development targeting US markets with annual sales greater than US$3bn1 ● 5 generic products filed with the FDA targeting US markets with annual sales of greater than US$400m1 ● 3 FDA approvals expected thi

  10. Slide 10: Research and development – branded pipeline

    Research and development – branded pipeline For personal use only Overview of SUBACAP® SUBACAP® market potential (Total market: US$530m1) • Significantly improved formulation of itraconazole (anti- fungal) based on SUBA® technology (improved bioavailability) 27% 28% Japan Europe  Conventional itrac

  11. Slide 11: Mayne Pharma – our strengths

    Mayne Pharma – our strengths For personal use only ● World-class modified release solid-dose formulation and manufacture – now in 2 locations ● 30 year track record of innovation and success in developing new oral pharmaceuticals for both generic and branded application including – SUBACAP®, Doryx®,

  12. Slide 12: Outlook

    Outlook For personal use only Future catalysts ● SUBACAP® launch in Europe for value ● US portfolio expansion through growing product pipeline ● File and partner SUBACAP® in US, Korea and Japan ● Deliver on key milestones for R&D program ● Re-launch Kapanol® in Australia ● Launch selected Mayne Phar

  13. Slide 13: A specialty pharmaceutical company with an increasingly diversified portfolio

    A specialty pharmaceutical company with an increasingly diversified For personal use only portfolio of products, technologies and footprint 13

Mayne Pharma Group — UBS Emerging Companies Conference 2013 on 6ix